Hennion & Walsh Asset Management Inc. Takes $724,000 Position in Prothena Co. plc (NASDAQ:PRTA)

Hennion & Walsh Asset Management Inc. bought a new position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 52,284 shares of the biotechnology company's stock, valued at approximately $724,000. Hennion & Walsh Asset Management Inc. owned approximately 0.10% of Prothena as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its position in shares of Prothena by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company's stock valued at $173,000 after acquiring an additional 4,026 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Prothena in the third quarter valued at approximately $210,000. XTX Topco Ltd bought a new position in shares of Prothena during the 3rd quarter worth approximately $260,000. Orion Portfolio Solutions LLC increased its holdings in shares of Prothena by 4.4% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock worth $293,000 after acquiring an additional 739 shares during the last quarter. Finally, Creative Planning bought a new stake in Prothena in the 3rd quarter valued at $350,000. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Trading Up 4.5 %

PRTA stock traded up $0.59 during mid-day trading on Monday, reaching $13.77. The company's stock had a trading volume of 543,598 shares, compared to its average volume of 693,724. The business's 50 day moving average price is $14.50 and its 200 day moving average price is $18.13. Prothena Co. plc has a 12 month low of $11.70 and a 12 month high of $34.75. The company has a market cap of $740.96 million, a price-to-earnings ratio of -5.55 and a beta of 0.10.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.18) by $0.08. The business had revenue of $0.97 million for the quarter, compared to analysts' expectations of $1.22 million. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The firm's revenue for the quarter was down 98.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 EPS. As a group, equities analysts expect that Prothena Co. plc will post -2.24 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on PRTA. StockNews.com lowered shares of Prothena from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. Bank of America cut their price objective on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating for the company in a research report on Thursday, December 19th. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 price objective (down from $84.00) on shares of Prothena in a report on Friday, December 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of Prothena in a report on Monday, September 30th. Finally, Chardan Capital started coverage on shares of Prothena in a report on Friday, December 20th. They set a "buy" rating and a $40.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $46.50.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.